Skip to main content

Table 2 Adverse events

From: Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer

 

nab-PTX plus RAM

PTX plus RAM

P value

(N = 113)

(N = 138)

 

Any grade (%)

>Grade 3 (%)

Any grade (%)

>Grade 3 (%)

Any grade

>Grade 3

All adverse events

112 (99.1)

76 (67.3)

134 (97.1)

88 (63.8)

0.254

0.563

Hematological

 Neutropenia

91 (80.5)

64 (56.6)

108 (78.3)

76 (55.1)

0.659

0.804

 Leukopenia

85 (75.2)

34 (30.1)

107 (77.5)

48 (34.8)

0.667

0.43

 Anemia

105 (92.9)

8 (7.1)

112 (81.2)

19 (13.8)

0.007

0.089

 Thrombocytopenia

43 (38.1)

6 (5.3)

35 (25.4)

4 (2.9)

0.031

0.258

Non-hematological

 Sensory neuropathy

72 (63.7)

2 (1.8)

51 (37.0)

0 (0.0)

0

0.202

 Fatigue

42 (37.2)

1 (0.9)

33 (23.9)

0 (0.0)

0.022

0.45

 Anorexia

33 (29.2)

1 (0.9)

29 (21.0)

1 (0.7)

0.134

0.699

 Nausea

17 (15.0)

2 (1.8)

18 (13.0)

1 (0.7)

0.649

0.425

 Diarrhea

7 (6.2)

0 (0.0)

14 (10.1)

0 (0.0)

0.261

 Stomatitis

10 (8.8)

0 (0.0)

14 (10.1)

1 (0.7)

0.728

0.55

 Edema

33 (29.2)

0 (0.0)

32 (23.2)

0 (0.0)

0.279

 Proteinuria

30 (26.5)

3 (2.7)

29 (21.0)

2 (1.4)

0.304

0.406

 Hypertension

30 (26.5)

15 (13.3)

27 (19.6)

9 (6.5)

0.189

0.07

 Febrile neutropenia

6 (5.1)

6 (5.1)

13 (9.4)

13 (9.4)

0.221

0.221

 Interstitial pneumonia

8 (7.1)

3 (2.7)

5 (3.6)

3 (2.2)

0.219

0.56

 Hypersensitivity reaction

0 (0.0)

0 (0.0)

2 (1.4)

2 (1.4)

  1. nab-PTX nanoparticle albumin-bound paclitaxel, RAM ramucirumab